Crux Map & Key Questions
The technical and empirical disagreements behind 2036 cost projections. Start with the five-card overview and open only what you need. Sources.
At a glance
Five questions raised by the discussion and written responses; each card is a direct link
Here a crux is a question whose answer would materially change the cost forecast, or the chance that the forecasted industry exists.
How to comment or respond
Three options, depending on how much you want to say
Scope and representation
Why this should not be read as a field-wide consensus map
Areas of rough agreement
Six points of convergence within the May workshop cohort—not field-wide conclusions
Where the May workshop cohort broadly agreed. Later independent responses challenge some of these points.
- Humbird's amino-acid inputs should be updated. GFI's December 2025 analysis obtained bulk supplier quotes for some amino acids at between a tenth and a half of the prices Humbird used. This is evidence about ingredient prices, not validation of a complete medium or commercial process, and it is a source claim rather than an established workshop consensus.
- Food-grade inputs were widely expected within the workshop cohort. All eight respondents to CM_17 estimated an 80–100% share of output in 2036. This is a share estimate, not a probability. Two independent answers were 10% and 85%. Counts, question wording, and limits.
- The workshop cohort expected precision fermentation to cut growth-factor costs; plant molecular farming was contested. Asked the probability that each pathway achieves meaningful cost reduction by 2036 (E6), all 7 workshop respondents gave precision fermentation 50% or more (median 80%). For plant molecular farming the same 7 split: median 50%, with three at 15% or below. Fuchs gave both pathways 100%; Swartz gave 80% and 10%. A later anonymous independent response questions whether these improvements close the full system-level cost gap. All E6 answers.
- Within the workshop cohort, the animal-welfare case was framed mainly as a timeline and probability question. Most participants expected CM to succeed at some scale. A later independent response questions whether animal cells can approach commodity-food economics at all, so this is not a field-wide consensus.
- Density alone is a misleading performance metric. Cell volume per milliliter, performance-to-cost ratio (Frohlich/Swartz), and protein/lipid content (Frohlich, McNulty) are more useful. There is not yet a shared standard metric for comparing bioprocess performance across scenarios.
- Critical data gaps currently limit model validation. Swartz (S3 transcript): "There's basically no published studies that really quantify feed conversion ratio — what it actually is. There's also no information about inclusion rates... very little information around what is the actual cost of equipment."
Sources: public S1 and S3 transcripts and consent-checked beliefs submissions
Crux map
Five cruxes identified from public S1/S3 material, beliefs data, and public-cleared written submissions · no S2 discussion used
A crux is a specific empirical or technical question where: (a) different answers lead to meaningfully different 2036 cost projections; (b) reasonable, well-informed people currently disagree; and (c) the question is in principle resolvable by evidence. The five cruxes below are ordered roughly from most-upstream to most-downstream in the production process.
Crux 1
Cell line engineering: performance cascade, not just growth factor independence
Commercially validated growth, density, media needs, and growth-factor dependence
Cell line strategy is the most upstream cost-relevant decision in CM production. As Kubinyecz (S1) put it: "Immortalisation strategy determines proliferation rates, achievable density, growth factor dependence, and media requirements." Gene editing is one tool; the crux is not specifically whether gene editing succeeds, but what level of cell line performance — across all these dimensions — is commercially validated by 2030–2036.
Key sources: Kubinyecz S1 framing; Fuchs CM_12/CM_13 beliefs form; Swartz CM_12 written comment; S3 transcript (GF pathway discussion)
Crux 2
Media: hydrolysate substitution and the limits of media cost reduction
Food-grade inputs are one step; full-system hydrolysate economics are another
Two distinct steps in media cost reduction are often conflated. Workshop participants were broadly aligned on the first and actively divided on the second.
The key unresolved question, as Swartz put it at the end of S1: "The biggest question for me is whether the hydrolysates can meet nutritional needs for high-density growth in suspension settings, and whether this is actually more economically efficient than using purified nutrients." The cost difference between a Humbird-type scenario (largely purified AAs) and a Fuchs-type scenario (near-full hydrolysate substitution) is substantial — but the specific disagreement between workshop participants is about whether full substitution is achievable and net cost-positive at commercial density, not about whether some substitution will happen.
Would be very interesting to know if feed/energy conversion is improved by small peptide uptake. That would be a strong justification for using hydrolysates that I don't see discussed much. — Elliot Swartz, S1 chat
Key sources: Fuchs S1 presentation; Swartz CM_12 written comment; Bomkamp CM_17; S1 chat log; S1 transcript discussion
Crux 3
Cell productivity: density, process mode, FCR, and the binding constraint
The interaction among output rate, media use, contamination risk, and capital
Even if media costs fall substantially, the remaining hard problems are cell productivity (density × growth rate × bioreactor occupancy) and capital costs. Swartz's pre-workshop submission: "Media costs will be quite low. Questions remain around productivity and capital costs."
There's basically no published studies that really quantify feed conversion ratio — what it actually is. There's also no information about inclusion rates — what inclusion rates are actually going to yield tasty products. There's also very little information around what is the actual cost of equipment. How much capital do you need to build a facility of a certain size? Is a scale-up or scale-out approach more prudent, given capital constraints? — Elliot Swartz, S3 transcript
Key sources: Swartz S3 transcript (data gaps); Frohlich S3 transcript (process mode, performance-to-cost ratio); Abraham S1 (density, bioreactor scale); S3 chat (density, metrics discussion)
Crux 4
The product target: what is the end-point, and how does it constrain cost?
The effective cultured-cell inclusion rate may matter more than pure biomass parity
This crux was not in the pre-workshop framing but emerged prominently in S3. It may be more fundamental than the cost cruxes above: if the product target is undefined or wrong, optimizing for biomass cost is optimizing the wrong thing.
You've got to start with the end in mind. A lot of the companies I've been consulting for, it's like, well, let's make this biomass slop and then figure out what to do with it. It should be the other way around: what are you trying to make, and therefore design the cell culture process to provide the ingredient that's of importance to the final product? — Bert Frohlich, S3 transcript
Key sources: Frohlich S3 transcript; McNulty S3 transcript; Bomkamp S3 transcript (inclusion rate, price parity framing)
Crux 5
Capital availability and industry survival: will the field reach dedicated-plant scale?
A path-to-commercialization question, distinct from conditional production cost
This crux is different in kind from Cruxes 1–4. Those concern what 2036 production costs will be if the industry reaches commercial scale. This one concerns whether it does. The workshop organizer noted in S3 that CDMO infrastructure is not the right focus for forecasting 2036 costs — "that's an intermediate testing ground" — but the capital question is real and unresolved.
Key sources: Swartz S3 transcript (capital, market shaping); Frohlich S3 transcript (government investment, GINA); Lattanzi beliefs form CM_02; public sector-funding reports
Key questions for skeptics
Six challenges from the more optimistic side; open one question at a time
In S3, David Reinstein asked: "What would we want to put forward to the skeptics? What would you want them to answer? What am I getting wrong here?" The six questions below are challenges that optimistic participants think a well-informed skeptic should address. They are not claims that skepticism is mistaken. For the strongest skeptical argument we have received, and the questions it puts back to optimists, see the skeptical case.
Q1 · Media costs
GFI's December 2025 analysis found bulk supplier quotes for key amino acids at between a tenth and a half of the prices in Humbird's projections. Given that, what is your revised estimate for basal media cost at food-grade, industrial scale in 2036, and what specific input or assumption prevents it from falling further?
What would update this: detailed bulk supplier data by amino acid type; experimental evidence on whether hydrolysates meet nutritional needs at commercial suspension density.
Where this question comes from
Q2 · Cell line performance trajectory
CHO cells in biopharma went from about 1–2 million cells/mL in the 1980s to over 100 million/mL under perfusion, over 40 years of focused optimization. Cultured-meat cell lines have had about 5–10 years. At what rate do you expect their performance to improve on the relevant metrics (density, feed conversion, growth-factor independence), and why would that rate differ from CHO's? What specific biological or engineering constraint sets the ceiling?
What would update this: published feed-conversion data for cultured-meat cell lines; density benchmarks from companies willing to share (even non-attributed); results from open academic programs (NICA, ACIB, FEASTS).
Where this question comes from
Q3 · Growth factor cost pathways
All 7 workshop respondents to E6 gave precision fermentation at least a 50% chance of meaningfully reducing growth-factor costs by 2036 (median 80%). They were split on plant molecular farming (median 50%). What is your probability for each, and what specific technical or commercial obstacle would prevent cost-competitive recombinant growth factors within a decade in at least one jurisdiction?
What would update this: demonstration at industrial fermentation scale; regulatory clearance for recombinant growth-factor use in cultured-meat production in at least one major jurisdiction.
Where this question comes from
Q4 · Inclusion rates and hybrid products
If a hybrid product (animal cells plus plant protein or mycoprotein) at 5–20% animal-cell inclusion can match conventional meat on taste and texture in relevant market segments, the cell-biomass cost needed for parity is 5 to 20 times higher than if the product were 100% animal cells. What is the minimum inclusion rate for a commercially viable product, and on what evidence?
What would update this: published sensory studies with varied inclusion rates; investor willingness-to-fund data on hybrid products; regulatory clarity on labelling for hybrid products.
Where this question comes from
Q5 · The learning-curve analogy
Solar PV and battery storage both saw 80–90% cost reductions over roughly a decade once manufacturing scaled up, driven by learning curves, R&D and competition. Swartz suggests a similar trajectory is plausible for cultured meat given enough capital. What would make its cost trajectory more like biopharma, where costs plateau because of biological and regulatory constraints? Is that a claim about biology, regulation, or market structure?
What would update this: evidence of learning-curve effects in early production runs; a demonstrated cost reduction from one pilot scale to the next within a single company.
Where this question comes from
Q6 · Regulatory and geographic scope
The US has a product-specific FDA consultation process, followed for amenable species by USDA-FSIS inspection and label approval; it has not broadly pre-cleared gene-edited cell lines. If early commercial scale is confined to the US and/or Singapore for 2026–2032, what does the cost trajectory look like, and does that change your 2036 estimate for the global cost frontier?
What would update this: completed consultations and inspection grants for defined products and processes; demonstrated commercial production at scale; decisions in additional jurisdictions; published regulator guidance specific to engineered cultured-animal cells.
Where this question comes from
Developed from public S3 discussion about what would change a skeptic's mind
Key questions for optimists
Three top-down stress tests from an anonymized independent argument
These three questions come from the anonymous independent respondent whose argument is set out on the skeptical case page. They are a stress test in the other direction, not an endorsement of that respondent's $500/kg median. The distinctive claim is that a top-down benchmark can reveal system-level constraints that bottom-up models miss.
We may reword O1 before the next round
Two independent respondents, reasoning from different mechanisms, argue that cell density and doubling time are the wrong lever for media cost. One reasons from nutrient consumption: cells use up the components of the medium, so higher density just needs more medium per kg. The other reasons from overflow metabolism. Both conclude that the cost-driving quantity is yield.
If they are right, density and productivity still matter, but for reactor volume and therefore capital, not media cost. O1 asks only about productivity, doubling time, occupancy and contamination loss, so it would miss the quantity the objection is about. Q2 already names feed conversion, but behind density.
We have not changed O1 yet. The objection rests on two respondents, and the counter-arguments (second-order volume savings, concentration limits, how much of media cost is nutrients rather than volume) have not been put to anyone. If you think O1 is right as written, that is a useful answer too.
O1 · Benchmark against mature fermentation
Estimate cultured-meat production cost top-down against yeast biomass production. What volumetric productivity (g/L/day), doubling time, reactor occupancy, and contamination loss do you assume for cultured animal cells in 2036, and how do those quantities compare with an industrial yeast process?
What would update this: a harmonized public comparison on the same output, facility, utilization, and cost basis; measured large-reactor productivity and loss rates.
Where this question comes from
O2 · Explain the economic floor
If mature yeast-derived single-cell protein remains in roughly the same price order as meat, what mechanism lets slower, more fragile animal cells, with more complex inputs and controls, reach or undercut the relevant meat benchmark? Which differences in product value or inclusion rate are doing the work?
What would update this: verified full-economic-cost data from commercial cultured-meat output; evidence separating biomass cost from product premium and hybrid inclusion effects.
Where this question comes from
O3 · Identify the fragile assumption
In your preferred bottom-up TEA, which single assumption would break the headline result if it were wrong by one order of magnitude? Which interactions among media use, growth, density, downtime, and capital could make several individually plausible assumptions fail jointly?
What would update this: structural sensitivity across independently built models, not only one-at-a-time parameter changes inside one model.
Where this question comes from
Added July 20, 2026 from a public-cleared anonymized argument; biographical and timing details withheld
Mechanisms behind the top-down critique
The stated causal chains, and the same respondent's read on three workshop claims
The full argument, in one readable piece, is on the skeptical case page. The questions above rest on specific claimed mechanisms rather than on a general pessimism. They are set out here so they can be argued with individually: each is a testable claim about why a cost gap persists, and each names what it would take to close it. The respondent's rough bound is a production-cost disadvantage against industrial yeast of about three orders of magnitude — roughly two from volumetric productivity and one from inputs — expected to still hold around 2036. That bound is offered as a benchmark to check optimistic productivity assumptions against, not as a forecast of a market price.
A structural argument that sits on top of the biology. A large, sustained gap is described as partly self-perpetuating: while cultured meat sits far from parity there is little private incentive to fund the deep, coordinated, largely non-appropriable R&D needed to reach even its biological floor, so that floor may not be realized. And because cost is a product of many drivers, isolated wins — cheaper growth factors, say — do not compose into a low headline cost unless media, productivity, senescence, and capital improve together. This matters for funders specifically: it is an argument about what coordinated funding would have to look like, not only about what the technology can reach.
A separate claim, raised as a gap in the field's own evidence: product quality is rarely measured in cultured-meat R&D, despite being central to whether the product is worth the cost — and where high-quality prototypes exist, much of the work is said to rest on conventional plant-based technique.
The same respondent on three workshop claims
Added September 2, 2026 from the same public-cleared anonymized argument as the questions above; biographical, institutional, and timing details withheld at the respondent's request
Implications for the cost model
Five concrete modeling changes implied by the crux map
The map suggests several places where the interactive cost model dashboard needs development or explicit scenario treatment:
Respond to the crux map
A useful response can be short: what you think, and what would change your mind. Everything else is optional. We especially want technically grounded skeptical responses, and answers from optimists to the top-down questions.
For a full numerical forecast (p10, median, p90), use the beliefs form. To comment on one sentence, use the Hypothes.is sidebar.